Pulse Biosciences (PLSE) analyst forecast and price target
Analyst forecast
Consensus of 6 analyst ratings
Based on 5 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $60.00 from $35.00 | Oct 13, 2026 |
| Canaccord Genuity | Maintained | Buy | $58.00 from $43.00 | Oct 6, 2026 |
| BTIG | Initiated Coverage | Buy | $70.00 | Sep 23, 2026 |
| Freedom Capital Markets | Initiated Coverage | Buy | $73.00 | Sep 9, 2026 |
| Needham | Initiated Coverage | Buy | $58.00 | Aug 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $43.00 from $32.00 | Aug 10, 2026 |
| Canaccord Genuity | Initiated Coverage | Buy | $32.00 | Jun 4, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $22.00 | Jul 7, 2025 |
Frequently asked questions
What is the price target for PLSE stock?
The average 12-month analyst price target for Pulse Biosciences (PLSE) is $63.80, with a high estimate of $73.00 and a low of $58.00, across 5 analysts.
Is PLSE a buy, sell, or hold?
Analysts covering Pulse Biosciences currently average a Buy rating: 6 buy, 0 hold and 0 sell, from 6 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for PLSE?
The average price target of $63.80 implies 41.33% upside from the last price of $45.14.
What is the latest analyst rating on PLSE?
On Oct 13, 2026, Oppenheimer maintained Pulse Biosciences at Outperform with a price target of $60.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.